COEPWMEDIUM SIGNALFINANCIAL10-K

Coeptis substantially expanded its asset base while meaningfully reducing liabilities, though operating losses deepened and cash position declined.

The company appears to have completed a significant balance sheet restructuring or financing event that roughly doubled total assets while cutting liabilities by more than half. However, the widening operating losses and declining cash position suggest ongoing operational challenges that require careful monitoring of the company's path to profitability.

Comparing 2026-03-19 vs 2025-03-28View on EDGAR →
FINANCIAL ANALYSIS

The financial picture shows a tale of two directions - a substantially strengthened balance sheet with total assets growing to $16.2M from $8.9M and total liabilities falling meaningfully to $2.1M from $5.0M, suggesting successful debt restructuring or new equity financing. However, operational metrics moved in the opposite direction with operating losses deepening to $13.0M and operating cash flow declining to negative $8.6M, while the cash position dropped to $404K from $907K, creating potential liquidity concerns despite the improved balance sheet structure.

FINANCIAL STATEMENT CHANGES
Total Assets
Balance Sheet
+81.3%
$8.9M$16.2M

Asset base grew 81.3% — expansion through organic growth, acquisitions, or capital deployment.

Current Liabilities
Balance Sheet
-60.8%
$4.5M$1.8M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-58.6%
$5.0M$2.1M

Liabilities reduced 58.6% — deleveraging improves balance sheet strength and financial flexibility.

Cash & Equivalents
Balance Sheet
-55.4%
$907K$404K

Cash declined 55.4% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Interest Expense
P&L
-50.7%
$218K$108K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

R&D Expense
P&L
-45.2%
$2.3M$1.3M

R&D spending cut 45.2% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
-29.7%
-$10.1M-$13.0M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Operating Cash Flow
Cash Flow
-29.4%
-$6.6M-$8.6M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

LANGUAGE CHANGES
NEW — 2026-03-19
PRIOR — 2025-03-28
ADDED
Management s Discussion and Analysis of Financial Condition and Results of Operations 32 7A.
This report includes our audited consolidated financial statements as of and for the years ended December 31, 2025 and December 31, 2024.
The biopharmaceutical division focuses on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases.
Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
The technology division focuses on enhancing operational capabilities through advanced technologies.
+7 more — sign up free →
REMOVED
Management s Discussion and Analysis of Financial Condition and Results of Operations 33 7A.
This report includes our audited consolidated financial statements as of and for the year ended December 31, 2024.
This report also includes our audited consolidated financial statements as of and for the year ended December 31, 2023.
Our current business model is designed around furthering the development of our current product portfolio.
Our biopharmaceutical division is continually exploring partnership opportunities with companies that have novel therapies in various stages of development or companies with technologies that improve the way that drugs are delivered to patients.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →